Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sandostatin Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 19, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

Palliative Management of Inoperable Malignant Bowel Obstruction

NCT04027348
View directory record Official record
Conditions
Malignant Bowel Obstruction
Interventions
Dexamethasone, Metoclopramide, Octreotide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

NCT00001228
View directory record Official record
Conditions
Islet Cell Adenoma, Zollinger Ellison Syndrome
Interventions
Interferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002864
View directory record Official record
Conditions
Breast Cancer
Interventions
octreotide acetate, tamoxifen citrate
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 19, 2026, 6:43 PM EDT
Withdrawn Phase 2 Interventional

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

NCT04276597
View directory record Official record
Conditions
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions
177Lu-DOTATOC
Drug
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT00257426
View directory record Official record
Conditions
Liver Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 19, 2026, 6:43 PM EDT
Not listed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

NCT03252353
View directory record Official record
Conditions
Acromegaly
Interventions
octreotide capsules, Matching placebo
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Octreotide on Saliva

NCT05340192
View directory record Official record
Conditions
Healthy
Interventions
Octreotide 1 MG/ML
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

NCT02916433
View directory record Official record
Conditions
Octreotide, Sputum
Interventions
Octreotide
Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

NCT00004895
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
octreotide acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

NCT00003057
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
loperamide hydrochloride, octreotide acetate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
33
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 19, 2026, 6:43 PM EDT
Completed No phase listed Observational

Stress, Diurnal Cortisol, and Breast Cancer Survival

NCT00226967
View directory record Official record
Conditions
Breast Cancer
Interventions
Sandostatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
35 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia

NCT00804297
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus
Interventions
Octreotide (drug)
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2008 · Synced Oct 19, 2026, 6:43 PM EDT
Terminated Early Phase 1 Interventional

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

NCT03001349
View directory record Official record
Conditions
Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Somatostatin Positive Neoplastic Cells Present, Von Hippel-Lindau Syndrome
Interventions
Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 19, 2026, 6:43 PM EDT
Not yet recruiting Phase 3 Interventional

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

NCT07842172
View directory record Official record
Conditions
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Interventions
Somatostatin Analogue(s)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

NCT00412061
View directory record Official record
Conditions
Carcinoid Tumor, Malignant Carcinoid Syndrome
Interventions
Octreotide, Placebo, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
38
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239
View directory record Official record
Conditions
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Interventions
Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Effect of Octreotide on the Colonic Motility in Pediatric Patients

NCT01917773
View directory record Official record
Conditions
Colonic Motility Index, Constipation
Interventions
Octreotide, Bisacodyl
Drug
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 19, 2026, 6:43 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 19, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

NCT00590343
View directory record Official record
Conditions
Metastatic Neuroendocrine Tumors
Interventions
vatalanib
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 19, 2026, 6:43 PM EDT